Antilysophosphatidic Acid Antibodies in the Treatment of Post-TBI Neuropathic Pain
Technical Report,15 Apr 2016,31 Oct 2019
Stanford University Palo Alto United States
Pagination or Media Count:
Lysophosphotidic acid LPA is a lipid imflammatory mediator that is released following nerve injury, including injury to the brain. LPA has been implicated in the development and maintenance of pain and other deleterious sequelae to brain injury. The broad, long-term goal of this project is to evaluate the therapeutic potential of a novel humanized anti-LPA antibody Lpathomab for attenuating post-traumatic brain injury TBI associated pain. Thus, we studied the effect of Lpathomab, comparing the utility of nasal, intravenous, and subcutaneous administration, in preventing long-term pain sequelae due to fluid percussion- induced neurotrauma in rats. We successfully implemented the rat model in our laboratory, which produced significant behavioral hypersensitivity. We then demonstrated, and published that nasally applied Lpathomab concentrated in the brain and inhibited post-TBI hypersensitivity. Due to technical issues, we did not complete testing of IV or IM application of Lpathomab or measure LPA in CSF.
- Medicine and Medical Research
- Weapons Effects (Biological)